GlassScriptPhysician profile
Mark B Jennings
NPI 1336379783
$3,977.06
in general payments reported to CMS, 2019-2025
45 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $285 · 2021: $242 · 2022: $555 · 2023: $818 · 2024: $738 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319 · Education: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.13 |
| Education | $965.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,245.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.61 | 2019-2025 | Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $214.73 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $162.87 | 2019 | |
| Caris Mpi, INC. | $140.77 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $135.04 | 2019-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $133.96 | 2020-2024 | Opdivo |
| Intuitive Surgical, INC. | $129.89 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $105.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.65 | 2020-2025 | |
| Astellas Pharma US INC | $91.91 | 2019-2025 | Vyloy, Padcev |
| Abbvie INC. | $89.97 | 2019-2025 | |
| Genentech USA, INC. | $87.88 | 2019-2022 | |
| Veran Medical Technologies, INC. | $83.99 | 2020 | |
| Glaxosmithkline, LLC. | $82.58 | 2021-2025 | Ojjaara |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.